Hepatocellular carcinoma (HCC) is the most frequent liver neoplasm, and its incidence rates
are constantly increasing. Despite the availability of potentially curative treatments (liver …

Hepatocellular carcinoma (HCC) is a morbid condition for which surgical and ablative
therapy are the only options for cure. Nonetheless, over half of patients treated with an R0 …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Background & Aims Resection is the most widely used potentially curative treatment for
patients with early hepatocellular carcinoma (HCC). However, recurrence within 2 years …

Objectives To develop radiomics-based nomograms for preoperative microvascular invasion
(MVI) and recurrence-free survival (RFS) prediction in patients with solitary hepatocellular …

PURPOSE To report the efficacy and safety of postoperative adjuvant hepatic arterial
infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular …

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …

Objective: We compared surgical resection (SR) and radiofrequency ablation (RFA) as first-
line treatment in patients with hepatocellular carcinoma (HCC) based on the risk of …

Importance The presence of microvascular invasion (MVI) decreases surgical outcomes of
hepatocellular carcinoma (HCC). An accurate preoperative prediction of MVI can help …

Background and Aims Lenvatinib is an effective drug in advanced HCC. Its combination with
the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor …